Los Angeles Capital Management
ONCE

Los Angeles Capital Management’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Los Angeles Capital Management’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3,050
Closed -$252K – 1540
2018
Q2 		$252K Sell
3,050
-960
-24% -$74.1K ﹤0.01% 1330
2018
Q1 		$267K Buy
+4,010
New +$232K ﹤0.01% 1200

Other funds holding ONCE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Los Angeles Capital Management's ONCE Position: Q3 2018 in Review

Los Angeles Capital Management sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q3 2018, closing a stake of 3,050 shares — an estimated $252K sold.

Los Angeles Capital Management first reported a position in ONCE in Q1 2018 and held it in 2 quarters. The position peaked at $267K in Q1 2018. 176 funds tracked by Wall St. Rank hold ONCE as of Q3 2018.

  • Los Angeles Capital Management reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Los Angeles Capital Management sold 3,050 Spark Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $252K.
  • Los Angeles Capital Management first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2018 and held it in 2 quarters.
  • Los Angeles Capital Management's Spark Therapeutics, Inc. Common Stock position peaked at $267K in Q1 2018.
  • 176 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Los Angeles Capital Management's 13F filing for Q3 2018, filed 5 Nov 2018.